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Abstract
Background: After the 2003 publication of the Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines, there was a 5–10% increase in patients initiating
antihypertensive medication with a thiazide-type diuretic, but most patients still did not initiate treatment with this class.
There are few contemporary published data on antihypertensive medication classes filled by patients initiating treatment.
Methods and Findings: We used the 5% random Medicare sample to study the initiation of antihypertensive medication
between 2007 and 2010. Initiation was defined by the first antihypertensive medication fill preceded by 365 days with no
antihypertensive medication fills. We restricted our analysis to beneficiaries $65 years who had two or more outpatient
visits with a hypertension diagnosis and full Medicare fee-for-service coverage for the 365 days prior to initiation of
antihypertensive medication. Between 2007 and 2010, 32,142 beneficiaries in the 5% Medicare sample initiated
antihypertensive medication. Initiation with a thiazide-type diuretic decreased from 19.2% in 2007 to 17.9% in 2010. No
other changes in medication classes initiated occurred over this period. Among those initiating antihypertensive medication
in 2010, 31.3% filled angiotensin-converting enzyme inhibitors (ACE-Is), 26.9% filled beta blockers, 17.2% filled calcium
channel blockers, and 14.4% filled angiotensin receptor blockers (ARBs). Initiation with .1 antihypertensive medication
class decreased from 25.6% in 2007 to 24.1% in 2010. Patients initiated .1 antihypertensive medication class most
commonly with a thiazide-type diuretic and either an ACE-I or ARB.
Conclusion: These results suggest that JNC 7 had a limited long-term impact on the choice of antihypertensive medication
class and provide baseline data prior to the publication of the 2014 Evidence-Based Guideline for the Management of High
Blood Pressure in Adults from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).
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Introduction
In 2002, the Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT) found that in a
hypertensive population with at least one additional coronary
heart disease (CHD) risk factor, randomization to chlorthalidone
(thiazide-type diuretic), amlodpine (calcium channel blocker
[CCB]), or lisinopril (angiotensin-converting enzyme inhibitor
[ACE-I]) was associated with similar rates of coronary heart
disease outcomes [1].Chlorthalidone was associated with a lower
risk of heart failure, a secondary outcome. Shortly after the
publication of the main results of ALLHAT, the Seventh Report of
the Joint National Committee on the Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC 7)
published guidelines for the prevention and treatment of
hypertension [2].
Based in part on the comparative effectiveness results shown in
ALLHAT, and due to their lower cost, JNC 7 supported the use of
thiazide-type diuretics as first line therapy for those without a
compelling indication for treatment with another antihypertensive
drug class. For patients with compelling indications (e.g. chronic
kidney disease [CKD]), use of other classes of antihypertensive
medication was recommended. Several studies have examined the
impact of ALLHAT and JNC 7 on classes of antihypertensive
medication being filled by patients initiating treatment [3–5].
These studies reported a 5–10% increase in the initiation of
antihypertensive treatment with thiazide-type diuretics after the
publication of ALLHAT and JNC 7. However, the majority of
patients initiated antihypertensive medication with other drug
classes during this period, indicating that JNC 7 guidelines had a
limited impact on the choice of drug class. There are few recent
data on whether adherence to JNC 7 drug class recommendations
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has increased or decreased over time. While it is possible that
thiazide-type diuretic usage has increased, ACE-Is and CCBs have
since decreased in cost [6,7]. Additionally, subsequent trials
comparing antihypertensive drug classes on cardiovascular
outcomes and a meta-analysis has suggested no substantial
differences exist between ACE-Is, angiotensin receptor blockers
(ARBs), CCBs, and thiazide-type diuretics [8–12].Also, guidelines
and policy statements from various associations and institutions
published since JNC 7 have not universally recommended
thiazide-type diuretics for patients initiating treatment [13–15].
These factors could influence current trends in choices of first-line
therapy among US adults.
The long-term impact of JNC 7 is of relevance to the current
and future dissemination of guidelines, such as the recently
published 2014 Evidence-Based Guideline for the Management of
High Blood Pressure in Adults from the Panel Members
Appointed to the Eighth Joint National Committee (JNC 8)
[16]. Contemporary data can provide a baseline documentation of
whether patients are initiating antihypertensive medication with
the classes recommended by JNC 8. Therefore, the goal of the
present study was to examine the classes of antihypertensive
medication being filled among US Medicare beneficiaries
initiating treatment. Additionally, we evaluated the association
between patient factors, including demographics and comorbid-
ities, with the initiation of antihypertensive medication classes. To
accomplish these goals, we analyzed the 5% random sample of US
Medicare beneficiaries initiating antihypertensive medication
between 2007 through 2010.
Methods
We conducted a retrospective cohort study of Medicare
beneficiaries using the 2006–2010 national 5% random sample
from the Centers for Medicare and Medicaid Services (CMS).
Medicare is a US federal benefit program that provides health
insurance to individuals 65 years of age and older, on disability, or
who have end-stage renal disease, through either individual fee-
for-service claims or contracts with health care organizations.
Specific data used for the current analyses include claims from
Medicare fee-for-service Parts A (in-patient), B (out-patient) and D
(prescription drug). These data provide Medicare claims data
linked by beneficiary across the continuum of care. The CMS and
the Institutional Review Board at the University of Alabama at
Birmingham approved the study. Beneficiary records were
anonymized and de-identified prior to analysis.
The current analysis included Medicare beneficiaries who
initiated antihypertensive medication in 2007, 2008, 2009 or
2010. The initial eligibility criterion was defined by filling an
antihypertensive medication between January 1, 2007 and
December 25, 2010. The date of each beneficiary’s first fill for
an antihypertensive medication in a calendar year was used as
their index fill date. December 25, 2010 rather than December 31,
2010 was chosen for the end of the study period to accommodate a
6 day period to identify additional antihypertensive medication
classes filled among patients initiating treatment (see below). To
facilitate the identification of prevalent antihypertensive medica-
tion users for exclusion from our analyses, beneficiaries were
required to have continuous full Medicare coverage (traditional
Medicare Parts A and B fee-for-service and Part D coverage) and
reside in the 50 United States or Washington DC for the 365 day
period preceding the index fill date. This period is referred to as
the ‘‘look-back’’ period. To capture medications filled as part of
the initial antihypertensive regimen, we required beneficiaries to
have full Medicare coverage for 6 days following their index fill
date.
To increase the likelihood that the antihypertensive medications
were filled to lower blood pressure, we limited the sample to
beneficiaries with hypertension, defined by $2 outpatient
physician evaluation and management claims, $7 days apart,
with International Classification of Diseases, 9th Revision (ICD-9)
diagnoses of 401.x (malignant, benign or unspecified essential
hypertension) during the look-back period. We excluded benefi-
ciaries who were prevalent users of antihypertensive medication
defined by any antihypertensive medication fills during the 365
day look-back period. Also, we excluded beneficiaries who were ,
65 years of age at the start of the 365 day look-back period or $
110 years of age on the date of the index antihypertensive
medication fill. To examine possible time trends, we initially
created separate yearly cohorts of beneficiaries initiating antihy-
pertensive medication in 2007, 2008, 2009, and 2010. A
beneficiary could potentially be counted in multiple years if they
had an antihypertensive medication fill more than 365 days prior
to the index fill. In subsequent analyses, we pooled the data to
create a single cohort that only included each beneficiary’s first
antihypertensive medication fill in the 2007–2010 time period. A
CONSORT diagram showing the inclusion/exclusion of Medi-
care beneficiaries is provided in Figure S1.
Antihypertensive medication fills
Claims for antihypertensive medications were identified in the
Medicare Part D file. Antihypertensive medications filled from the
index fill date through the next 6 days were considered to be
initiated as part of the same regimen. Antihypertensive medica-
tions were grouped into drug classes using classifications from JNC
7, with newer medications identified by review of the study authors
(D.S., S.O.). Pills containing two antihypertensive medication
classes were considered combination medications and patients
were considered to initiate both classes.
Covariates
A priori-selected covariates were used to study the character-
istics of Medicare beneficiaries initiating each class of antihyper-
tensive medication. These included age, sex, race/ethnicity,
Medicaid buy-in (a measure of poverty) for the entire look-back
period, and comorbid conditions that may be considered
compelling indications for being prescribed certain antihyperten-
sive medication classes (diabetes, coronary heart disease [CHD],
stroke, CKD, and heart failure) [2]. Age, sex, race/ethnicity, and
Medicaid buy-in were defined using the Medicare beneficiary
enrollment file. Comorbid conditions were defined using claims
during the look-back period and previously published algorithms
(Appendix S1).
Statistical analyses
Characteristics of Medicare beneficiaries initiating antihyper-
tensive medications were calculated by calendar year of initiation.
For each calendar year, the percentages initiating each antihy-
pertensive medication class, initiating .1 class, and initiating
antihypertensive treatment with a combination pill were calculat-
ed. Among those who initiated therapy with .1 antihypertensive
medication class, we examined the pairs of classes that were
initiated. P-values for trends across calendar year were calculated
in Poisson regression models with calendar year as a continuous
variable. Using the pooled 2007–2010 cohort, we calculated the
distributions of antihypertensive medication classes initiated for
the overall population and in subgroups defined by gender, race/
ethnicity (black, white, Hispanic, Asian, or other), the presence or
Antihypertensive Medication Initiation in Medicare
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e105888
absence of each compelling indication (diabetes, CHD, stroke,
CKD, and heart failure), and with any or no compelling
indication, separately. We then calculated the risk ratios for
initiating each antihypertensive medication class using Poisson
regression and sandwich estimators. Initiating each antihyperten-
sive medication class was evaluated in a separate regression model
with the comparison group consisting of individuals initiating an
antihypertensive medication regimen without that class (e.g.,
initiating with an ACE-I versus initiating treatment with any other
antihypertensive medication classes). Adjusted risk ratios for
initiating each antihypertensive medication class were calculated
for calendar year of initiation, age, gender, race/ethnicity,
Medicaid buy-in, diabetes, CHD, CKD, and heart failure.
Adjusted risk ratios for initiating each antihypertensive medication
class were also calculated among Medicare beneficiaries without
any compelling indications. Lastly, we calculated the percent of
beneficiaries in the pooled 2007–2010 cohort who initiated
antihypertensive medication with classes recommended by the
2014 JNC 8 guideline. Among beneficiaries without CKD,
recommended classes include a thiazide-type diuretic or a CCB
for blacks and a thiazide-type diuretic, CCB, ACE-I, or ARB for
non-blacks [16]. For beneficiaries with CKD, recommended
classes include an ACE-I or an ARB. Analyses were conducted
using SAS 9.3 (SAS Institute, Cary, NC).
Results
In 2007, 2008, 2009, and 2010 there were 7,456, 8,769, 8,575,
and 8,719 eligible Medicare beneficiaries, respectively, who
initiated antihypertensive medication. Characteristics of Medicare
beneficiaries in the 5% sample who initiated antihypertensive
medications in 2007, 2008, 2009 and 2010 are provided in
Table 1. The mean age was 77 years, approximately 80% were
white and 37% to 41% were men. Diabetes was the most prevalent
comorbid condition, followed by a history of CHD. In each year,
approximately 50% of Medicare beneficiaries who initiated
antihypertensive medication had a history of diabetes, CHD,
stroke, CKD or heart failure. Beneficiaries initiating therapy in
later study years were younger and more likely to be male, white,
and have diabetes and CKD, and less likely to be black and have
had a stroke or heart failure. The presence of any compelling
indication (diabetes, CHD, stroke, CKD, and heart failure) for
being prescribed certain antihypertensive medication classes was
more common in recent study years.
ACE-Is were the most commonly initiated antihypertensive
medication class in each year (Table 2). The next most commonly
initiated medication classes were beta blockers, thiazide-type
diuretics, CCBs, and ARBs. Between 24% and 26% of the cohort
initiated antihypertensive medication with .1 class and 11% to
12% initiated treatment with a combination pill. Among those
who initiated multiple classes (either with a combination pill or as
separate pills), a thiazide-type diuretic with an ACE-I or a
thiazide-type diuretic with an ARB were mostly commonly
initiated (Table S1). Other antihypertensive medication pairs
commonly initiated were an ACE-I with a beta blocker or an
ACE-I with a CCB.
Overall, 32,142 Medicare beneficiaries were included in the
pooled 2007–2010 cohort. Figure 1 shows antihypertensive
medication classes initiated by beneficiary characteristics in this
cohort. Compared to females, males were more likely to initiate
antihypertensive medication with an ACE-I or beta blocker and
less likely to initiate treatment with an ARB or a thiazide-type
diuretic. Compared to whites, blacks were more likely to initiate
treatment with a thiazide-type diuretic or CCB. Compared to their
counterparts without diabetes, beneficiaries with diabetes were
more likely to initiate therapy with an ACE-I and less likely to
initiate with a thiazide-type or CCB. Those with CHD, stroke,
CKD, or heart failure were less likely than those without each
respective condition to initiate treatment with an ARB or with a
thiazide-type diuretic and more likely to initiate with a loop
diuretic or a beta blocker. Those without any compelling
indication (diabetes, CHD, stroke, CKD, or heart failure),
compared to those with any compelling indication, were less
likely to initiate therapy with an ACE-I or beta blocker and more
likely to initiate with an ARB or thiazide-type diuretic. Blacks
compared with whites, and those with diabetes, a history of stroke,
CKD, and heart failure were more likely to initiate treatment with
.1 antihypertensive class.
After multivariable adjustment, there was a decline in the
initiation of antihypertensive medication with a thiazide-type
diuretic over time (Table 3). Specifically, an 8% reduction (risk
ratio 0.92; 95% CI 0.86–0.98) in initiation of antihypertensive
medication with a thiazide-type diuretic occurred in 2010,
compared with 2007. Drug initiation patterns by each compelling
indication were similar to those in unadjusted analyses. Older
beneficiaries were less likely to initiate treatment with an ACE-I or
thiazide-type diuretic and more likely to initiate with a loop
diuretic, beta blocker, or CCB. Males were more likely than
females to initiate with an ACE-I and were less likely to initiate
with an ARB or a thiazide-type or potassium-sparing diuretic.
Compared to females, males were more likely to initiate with an
ACE-I and less likely to initiate with and ARB, or a thiazide-type
or potassium-sparing diuretic. Compared to whites, blacks were
less likely to initiate treatment with an ACE-I or loop diuretic and
more likely to initiate treatment with a thiazide-type diuretic or
CCB. Compared to whites, Hispanics were more likely to initiate
antihypertensive medication with an ACE-I or ARB and less likely
to initiate with a loop or potassium-sparing diuretic. Asians,
compared with whites were more likely to initiate with an ARB or
CCB and less likely to initiate treatment with an ACE-I or loop
diuretic. Beneficiaries with a Medicaid buy-in were less likely to
initiate treatment with an ARB or a thiazide-type or potassium-
sparing diuretic, and were more likely to initiate therapy with a
loop diuretic.
Drug initiation patterns were similar when limited to benefi-
ciaries without any compelling indications (Table S2). Specifically,
in both the overall pooled cohort and among those without any
compelling indications, initiation with a thiazide-type diuretic was
less common in later study years, and more common in younger,
female, and black beneficiaries. One notable difference is that in
the overall cohort there was no time trend for initiation with a loop
diuretic, but among those without compelling indications loop
diuretics were more commonly initiated in later years.
Among beneficiaries in the pooled 2007–2010 cohort, 19,891
(61.9%) initiated antihypertensive treatment with a medication
class recommended by JNC 8. Among beneficiaries without CKD,
48.8% of blacks and 66.7% of non-blacks initiated antihyperten-
sive medication with a drug class recommended by JNC 8. Among
beneficiaries with CKD, 34.3% initiated antihypertensive medi-
cation with an ACE-I or ARB (30.7% of blacks and 34.9% of non-
blacks).
Discussion
In the current study of a national sample of older hypertensive
US adults we found ACE-Is to be the most commonly initiated
class of antihypertensive medication, followed by beta blockers,
thiazide-type diuretics, CCBs, and ARBs. Initiation of antihyper-
Antihypertensive Medication Initiation in Medicare
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tensive medication with a thiazide-type diuretic decreased from
19.2% in 2007 to 17.9% in 2010. No other changes in initiation
rates by class occurred between 2007 and 2010. Younger age,
female sex, and black race were each associated with a higher
likelihood for initiating antihypertensive treatment with a thiazide-
type diuretic. However, initiating antihypertensive treatment with
a thiazide-type diuretic was uncommon (,30%) in all of the
subgroups investigated. Additionally, the percent of beneficiaries
initiating antihypertensive treatment with multiple medication
classes declined over time from 25.6% in 2007 to 24.1% in 2010.
In 2003, JNC 7 recommended thiazide-type diuretics for
patients with uncomplicated hypertension initiating antihyperten-
sive treatment [2]. Several studies have found that initiation of
antihypertensive treatment with a thiazide-type diuretic increased
after the publication of JNC 7 [3–5]. For example, an analysis of
data from a national network of clinics in the US found that the
percentage of patients initiating antihypertensive medication with
Table 1. Characteristics of Medicare beneficiaries initiating antihypertensive medication, by calendar year.
Calendar year
Characteristic 2007 (n =7456) 2008 (n =8769) 2009 (n =8575) 2010 (n =8719) p-value for trend
Age, years 77.0 (7.6) 77.1 (7.7) 76.8 (7.6) 76.7 (7.6) ,0.001
Male 2753 (36.9%) 3310 (37.7%) 3368 (39.3%) 3540 (40.6%) ,0.001
Race/ethnicity
White 5933 (79.6%) 7117 (81.2%) 7015 (81.8%) 7189 (82.5%) ,0.001
Black 826 (11.1%) 914 (10.4%) 771 (9.0%) 775 (8.9%) ,0.001
Hispanic 270 (3.6%) 301 (3.4%) 307 (3.6%) 283 (3.2%) 0.27
Asian 220 (3.0%) 220 (2.5%) 274 (3.2%) 252 (2.9%) 0.48
Other 207 (2.8%) 217 (2.5%) 208 (2.4%) 220 (2.5%) 0.32
Medicaid buy-in 2007 (26.9%) 1977 (22.5%) 1916 (22.3%) 1857 (21.3%) ,0.001
Diabetes 1966 (26.4%) 2329 (26.6%) 2346 (27.4%) 2463 (28.2%) 0.003
Coronary heart disease 1310 (17.6%) 1496 (17.1%) 1524 (17.8%) 1516 (17.4%) 0.90
Stroke 583 (7.8%) 661 (7.5%) 583 (6.8%) 600 (6.9%) 0.006
Chronic kidney disease 666 (8.9%) 840 (9.6%) 905 (10.6%) 1041 (11.9%) ,0.001
Heart failure 861 (11.5%) 941 (10.7%) 867 (10.1%) 925 (10.6%) 0.03
Any compelling indication{ 3585 (48.1%) 4260 (48.6%) 4207 (49.1%) 4394 (50.4%) 0.002
Numbers in table are mean (standard deviation) for age and number (percent) for other characteristics.
{Others include alpha blockers, central acting agents, direct vasodilators, aldosterone receptor blockers, and renin inhibitors.
doi:10.1371/journal.pone.0105888.t001
Table 2. Antihypertensive medication classes initiated among Medicare beneficiaries, by calendar year.
Calendar year
Antihypertensive medication class 2007 (n=7456) 2008 (n =8769) 2009 (n =8575) 2010 (n=8719)
p-value for
trend
Renin angiotensin system blockers 3416 (45.8%) 3919 (44.7%) 3914 (45.6%) 3977 (45.6%) 0.82
ACE-inhibitors 2380 (31.9%) 2662 (30.4%) 2712 (31.6%) 2728 (31.3%) 0.87
Angiotensin receptor blockers 1057 (14.2%) 1280 (14.6%) 1214 (14.2%) 1257 (14.4%) 0.90
All Diuretics 2540 (34.1%) 2999 (34.2%) 2845 (33.2%) 2833 (32.5%) 0.03
Thiazide 1433 (19.2%) 1686 (19.2%) 1616 (18.8%) 1565 (17.9%) 0.03
Loop 929 (12.5%) 1094 (12.5%) 1070 (12.5%) 1090 (12.5%) 0.94
Potassium-sparing 230 (3.1%) 291 (3.3%) 241 (2.8%) 241 (2.8%) 0.06
Beta blockers 2009 (26.9%) 2347 (26.8%) 2290 (26.7%) 2344 (26.9%) 0.93
Calcium channel blockers 1322 (17.7%) 1552 (17.7%) 1442 (16.8%) 1503 (17.2%) 0.21
Others{ 417 (5.6%) 481 (5.5%) 489 (5.7%) 527 (6.0%) 0.16
Initiating .1 antihypertensive medication class 1908 (25.6%) 2163 (24.7%) 2090 (24.4%) 2102 (24.1%) 0.03
Initiating a combination pill 899 (12.1%) 993 (11.3%) 963 (11.2%) 966 (11.1%) 0.06
Numbers in table are number (percent).
Numbers of antihypertensive medications initiated are not mutually exclusive; column percentages add to .100%.
Abbreviations: ACE = angiotensin-converting enzyme.
{Others include alpha blockers, central acting agents, direct vasodilators, aldosterone receptor blockers, and renin inhibitors.
doi:10.1371/journal.pone.0105888.t002
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a thiazide-type diuretic increased from 29% to 39% after
publication of JNC 7 [5]. However, a more recent study in a
separate national network of clinics found that only 16% of
patients on antihypertensive monotherapy initiated with a
thiazide-type diuretic [17]. Results of the current analysis are
consistent with the published literature in suggesting that despite
the recommendations of the JNC 7 guideline, the majority of US
patients do not initiate antihypertensive treatment with a thiazide-
type diuretic. Data from the current study also suggest that the
proportion of patients initiating antihypertensive medication with
a thiazide-type diuretic has decreased modestly in recent years,
despite an initial increase following publication of JNC 7. The
current study found that the percentages of patients initiating
antihypertensive treatment with an ACE-I or CCB were about
31% and 17%, respectively, similar to what has been reported in
literature examining initiation rates in the early 2000s [4,5].
Randomized controlled trials following the publication of
ALLHAT and JNC 7 that compared cardiovascular risk reduction
associated with taking CCBs, ACE-Is, and thiazide-type diuretics
have produced mixed results [8–11]. For example, in 2008 a large
randomized trial conducted in a high cardiovascular risk
hypertensive population reported that combination therapy with
an ACE-I and a CCB was superior to the same ACE-I combined
with a thiazide-type diuretic in preventing the composite outcome
of death from cardiovascular causes, nonfatal myocardial infarc-
tion, nonfatal stroke, hospitalization for angina, resuscitation after
sudden cardiac arrest, and coronary revascularization (hazard
ratio: 0.80; 95% CI: 0.72–0.90) [8]. However, other trials did not
find differences in cardiovascular risk associated with ACE-Is [11]
or CCBs [10] versus thiazide-type diuretics. In a 2009 pooled
analysis of 46 randomized control trials comparing beta blockers,
ACE-Is, ARBs, CCBs and thiazide-type diuretics, no drug classes
were found to be more effective than others in reducing the
incidence of CHD [9]. While CCBs were more effective in
preventing stroke compared to other drug classes (relative risk:
0.91; 95% CI: 0.84–0.98), they were less effective in preventing
heart failure (relative risk: 1.22; 95% CI: 1.10–1.35). Despite these
data, between 2007 and 2010 we found a slight decline in thiazide-
type diuretic initiation but did not find a corresponding trend of
increasing initiation with an ACE-I or CCB.
Several recent studies have examined prevalent use of
antihypertensive medication classes among US adults. The US
National Health and Nutrition Examination Survey (NHANES)
provide nationally representative data for prevalent antihyperten-
Figure 1. Antihypertensive medication classes initiated among Medicare beneficiaries, by selected covariates. Note: Compelling
indication is defined by a beneficiary having diabetes, coronary heart disease, stroke, chronic kidney disease, or heart failure. *p,0.05. {Any
compelling indication is defined as having diabetes, coronary heart disease, stroke, chronic kidney disease, or heart failure.
doi:10.1371/journal.pone.0105888.g001
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sive medication use. In an analysis of serial NHANES, the overall
percentage of individuals with hypertension taking thiazide-type
diuretics rose from 22% in 2001–2002 to 28% in 2009–2010 [18].
However, this analysis also found that the percentage of
individuals taking ACE-Is, beta blockers, CCBs, or ARBs all rose
over the past decade. In addition, antihypertensive polypharmacy
has increased over the past decade. Between 2001–2002 and
2009–2010, the percent of US adults with hypertension taking 2 or
more classes of antihypertensive medications increased from 37%
to 48% [18]. The current study found that the percentage of older
US adults initiating antihypertensive treatment with 2 or more
classes of medication decreased, albeit modestly, between 2007
and 2010. In the context of the published literature on prevalent
antihypertensive medication use, the findings from the current
study suggest that patients are increasingly initiating antihyper-
tensive medication with a single class and are subsequently up-
titrated to a regimen that includes multiple classes of antihyper-
tensive medication to control blood pressure. This interpretation is
supported by a recent study which found that, following
publication of JNC 7, patients were initiating antihypertensive
medications at a lower systolic and diastolic blood pressure
threshold, and thus were less likely to have an indication for
multiple classes of medications at the start of therapy [19].
The current study provides data on antihypertensive medication
initiation patterns among older US adults in the time period
between publication of the JNC 7 and JNC 8 guidelines. Whereas
JNC 7 recommended a thiazide-type diuretic as first-line therapy
for newly diagnosed patients with hypertension and no other
compelling indications, the recently published JNC 8 guideline
suggests that in the general nonblack population, including those
with diabetes, the initial antihypertensive treatment regimen
should include a thiazide-type diuretic, CCB, ACE-I, or ARB.
In the general black population, initial antihypertensive treatment
should include a thiazide-type diuretic or CCB. Other classes of
antihypertensive medication (e.g., beta blockers, alpha blockers)
are not recommended for use as first-line antihypertensive therapy
in the JNC 8 guideline. Whereas JNC 7 listed several comorbid-
ities that were compelling indications for specific medication
classes, JNC 8 only recommended an ACE-I or ARB for those
with CKD. We found that 61.9% of Medicare beneficiaries
initiated antihypertensive medication in 2007–2010 with an
antihypertensive medication class recommended by JNC 8. While
this compares favorably to studies that have consistently shown
that,40% of patients initiated antihypertensive medication with a
thiazide-type diuretic following JNC 7, whether the JNC 8
guideline will affect treatment regimens for patients initiating
antihypertensive medication is not yet known and should be
investigated in future studies.
Our study has several strengths. We used national data on US
adults 65 years of age and older from Medicare. Identifying
treatment patterns among older adults is important given their
high incidence of hypertension [20] and increased risk for adverse
blood pressure-related outcomes including CHD, stroke and end-
stage renal disease [21]. Most prior studies have relied on
prevalent users of antihypertensive medication. Using Medicare,
we were able to assess the initiation of, and secular trends in,
antihypertensive medication classes through 2010. This study also
has limitations. As with all claims-based analyses, our results
depend on the accuracy of claims to identify comorbid conditions
and pharmacy fills. While claims-based algorithms for CHD,
stroke, diabetes and heart failure have high positive predictive
value, algorithms for identifying CKD in Medicare do not [22]. In
addition, some beneficiaries may not have submitted claims for
reimbursement when initiating antihypertensive medication.
However, prior studies suggest that out-of-pocket payments for
generic medications among Medicare beneficiaries are not
common [23].
Conclusions
Despite the recommendation in JNC 7, in this nationwide study,
less than 1 in 5 Medicare beneficiaries initiated antihypertensive
medication with a thiazide-type diuretic. The proportion initiating
antihypertensive treatment with a thiazide-type diuretic was
higher in those without comorbid conditions, but remained below
30% in every subgroup investigated. These data suggest a
disconnect between US national guidelines and clinical practice
for the treatment of hypertension. Over 30% of Medicare
beneficiaries initiated antihypertensive medication with drug
classes not recommended as first line therapy in the 2014 JNC 8
guideline. Effective dissemination efforts for the JNC 8 guideline
are needed to ensure that patients receive appropriate antihyper-
tensive treatment.
Supporting Information
Figure S1 CONSORT diagram for the analysis Medi-
care beneficiaries initiating antihypertensive treatment.
(PNG)
Table S1 Most common pairs of antihypertensive
medication classes initiated in the pooled 2007–2010
5% Medicare sample who initiated .1 antihypertensive
medication, by calendar year.
(DOCX)
Table S2 Multivariable adjusted risk ratios for initiat-
ing each antihypertensive medication class in the pooled
2007–2010 5% Medicare sample without any compelling
indication.
(DOCX)




Conceived and designed the experiments: STK PM. Analyzed the data:
LH. Wrote the paper: STK. Supervised the project: STK PM. Provided
medical expertise and input into the study design: SO DS. Contributed to
the design of the analyses and provided interpretation of the results: LH.
Provided Medicare data expertise and guidance of interpretation of the
results: MLK PM. Critical review of the manuscript for content: STK PM
DS SO LH MLK KMD.
References
1. Allhat Officers and Coordinators for the Allhat Collaborative Research Group
The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial
(2002) Major outcomes in high-risk hypertensive patients randomized to
angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT). JAMA 288: 2981–2997.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA
289: 2560–2572. doi: 10.1001/jama.289.19.2560.
3. Xie F, Petitti DB, Chen W (2005) Prescribing patterns for antihypertensive drugs
after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Antihypertensive Medication Initiation in Medicare
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e105888
Attack Trial: report of experience in a health maintenance organization.
Am J Hypertens 18: 464–469. doi: 10.1016/j.amjhyper.2004.11.004.
4. Muntner P, Krousel-Wood M, Hyre AD, Stanley E, Cushman WC, et al. (2009)
Antihypertensive prescriptions for newly treated patients before and after the
main antihypertensive and lipid-lowering treatment to prevent heart attack trial
results and seventh report of the joint national committee on prevention,
detection, evaluation, and treatment of high blood pressure guidelines.
Hypertension 53: 617–623. doi: 10.1161/HYPERTENSIONAHA.108.120154.
5. Player MS, Gill JM, Fagan HB, Mainous AG, 3rd (2006) Antihypertensive
prescribing practices: impact of the antihypertensive and lipid-lowering
treatment to prevent heart attack trial. J Clin Hypertens (Greenwich) 8: 860–
864.
6. Bian B, Kelton CM, Guo JJ, Wigle PR (2010) ACE Inhibitor and ARB
utilization and expenditures in the Medicaid fee-for-service program from 1991
to 2008. J Manag Care Pharm 16: 671–679.
7. Brendt ER, Aitken ML (2011) Brand Loyalty, Generic Entry and Price
Competition in Pharmaceuticals in the Quarter Century after the 1984
Waxman-Hatch Legislation. Int J Econ Bus 18: 177–201.
8. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, et al. (2008) Benazepril
plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 359: 2417–2428. doi: 10.1056/NEJMoa0806182.
9. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in
the prevention of cardiovascular disease: meta-analysis of 147 randomised trials
in the context of expectations from prospective epidemiological studies. BMJ
338: b1665. doi: 10.1136/bmj.b1665.
10. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, et al. (2003)
Principal results of the Controlled Onset Verapamil Investigation of Cardiovas-
cular End Points (CONVINCE) trial. JAMA 289: 2073–2082. doi: 10.1001/
jama.289.16.2073.
11. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, et al. (2003) A comparison
of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for
hypertension in the elderly. N Engl J Med 348: 583–592. doi: 10.1056/
NEJMoa021716.
12. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, et al. (2003)
Treatment of isolated systolic hypertension: the SHELL study results. Blood
Press 12: 160–167.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007
Guidelines for the Management of Arterial Hypertension: The Task Force for
the Management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens 25: 1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.
14. Whitworth JA, World Health Organization ISoHWG (2003) 2003 World Health
Organization (WHO)/International Society of Hypertension (ISH) statement on
management of hypertension. J Hypertens 21: 1983–1992. doi: 10.1097/
01.hjh.0000084751.37215.d2.
15. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, et al. (2007) Treatment
of hypertension in the prevention and management of ischemic heart disease: a
scientific statement from the American Heart Association Council for High
Blood Pressure Research and the Councils on Clinical Cardiology and
Epidemiology and Prevention. Circulation 115: 2761–2788. doi: 10.1161/
CIRCULATIONAHA.107.183885.
16. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al.
(2013) 2014 Evidence-Based Guideline for the Management of High Blood
Pressure in Adults: Report From the Panel Members Appointed to the Eighth
Joint National Committee (JNC 8). JAMA. December 18, 2013 ed.
17. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, et al. (2012)
Initial monotherapy and combination therapy and hypertension control the first
year. Hypertension 59: 1124–1131. doi: 10.1161/HYPERTENSIO-
NAHA.112.194167.
18. Gu Q, Burt VL, Dillon CF, Yoon S (2012) Trends in antihypertensive
medication use and blood pressure control among United States adults with
hypertension: the National Health And Nutrition Examination Survey, 2001 to
2010. Circulation 126: 2105–2114. doi: 10.1161/CIRCULATIO-
NAHA.112.096156.
19. Krousel-Wood M, Muntner P, Carson A, Anderson AH, Delaune E, et al. (2012)
Hypertension control among newly treated patients before and after publication
of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens
(Greenwich) 14: 277–283. doi: 10.1111/j.1751-7176.2012.00609.x.
20. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, et al. (2011) Ethnic
differences in hypertension incidence among middle-aged and older adults: the
multi-ethnic study of atherosclerosis. Hypertension 57: 1101–1107. doi:
10.1161/HYPERTENSIONAHA.110.168005.
21. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Heart
disease and stroke statistics–2014 update: a report from the american heart
association. Circulation 129: e28–e292. doi: 10.1161/01.cir.0000441139.02102.
80.
22. Vlasschaert ME, Bejaimal SA, Hackam DG, Quinn R, Cuerden MS, et al.
(2011) Validity of administrative database coding for kidney disease: a systematic
review. Am J Kidney Dis 57: 29–43. doi: 10.1053/j.ajkd.2010.08.031.
23. Yun H, Curtis JR, Saag K, Kilgore M, Muntner P, et al. (2013) Generic
alendronate use among Medicare beneficiaries: are Part D data complete?
Pharmacoepidemiol Drug Saf 22: 55–63. doi: 10.1002/pds.3361.
Antihypertensive Medication Initiation in Medicare
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e105888
